Company intelligence / Profile preview

Tarpan Therapeutics

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Topical PTH (1-34) showed encouraging lesion clearing rates and safety in a small Phase 1/2 study; development continued in a Phase 2a trial after the merger, with formulation optimization but no approved products.

Therapeutic areas: Dermatology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Development license for PTH (1-34) with IGI, Inc.

Beyond the preview

Go deeper on Tarpan Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarpan Therapeutics.

Explore the full profile